Merck, Inc.
🇵🇭Philippines
The Canadian Follow-up Program for the ATTRACT Study (P04868)(TERMINATED)
Terminated
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Other: Retrospective Chart Review and Data collection
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00748930
Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)
Completed
- Conditions
- Melanoma
- Interventions
- Biological: Interferon α-2b
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 138
- Registration Number
- NCT00749684
A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
Completed
- Conditions
- Breast NeoplasmsOvarian NeoplasmsParesthesia
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 154
- Registration Number
- NCT00746694
A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Prednisone 7.5 mgDrug: Placebo TabletsDrug: Prednisone 15 mgDrug: Placebo Over-Encapsulated Tablets
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00746512
A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)
Phase 3
Terminated
- Conditions
- HIV
- Interventions
- Drug: TRUVADA™
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 775
- Registration Number
- NCT00745823
Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)
Completed
- Conditions
- Ovarian Neoplasms
- Interventions
- Drug: Caelyx (Pegylated Lyposomal Doxorubicin)
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 224
- Registration Number
- NCT00743431
A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 363
- Registration Number
- NCT00741104
Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Phase 2
Completed
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT00739830
Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)
Phase 2
Completed
- Conditions
- Breast CancerBreast Neoplasms
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT00736970
V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
Phase 1
Completed
- Conditions
- Staphylococcal Infection
- Interventions
- Biological: PlaceboBiological: V710
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00735839
© Copyright 2025. All Rights Reserved by MedPath